GlobeNewsWire
06 Oct 2026, 00:27 UTC · 1h ago
AARDVARK THERAPEUTICS (NASDAQ: AARD) SECURITIES CLASS ACTION: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Investors to Secure Counsel Before Important October 13 Deadline
Impact · against what's priced in
The news is a negligible catalyst for SMPL as the price already incorporates the risk of securities fraud litigation. For AARD and TIGO, the class action allegations regarding drug safety and misleading statements represent material negative risks to their pipeline valuations.
- SMPL−0.05
Already priced in
- The price assumes
A securities fraud class action lawsuit stemming from alleged misrepresentations about the OWYN integration.





